







Licensed products in pre-clinical & clinical phases

Reference	Indication	R+D	Pre-clinical	Phase I	Phase II	Phase III	Licensed	Research group
EYE-SCAFF project	LSCD syndrome	▶						CB06/01/0003
Procedure for the procurement of solid micro- or nanoparticles	New types of administration of medicines	▶						CB06/01/0033
Targeted delivery of therapeutic molecules to CXCR4 cells	Colorectal cancer	▶						CB06/01/0014 CB06/01/1031
Nanostructured proteins	Cancer	▶						CB06/01/0014 CB06/01/1031
Therapeutic nanoconjugates	Cancer	▶						CB06/01/0014 CB06/01/1031
Functionalized liposomes for delivery of biactive compounds	Fabry disease	▶					Undisclosed	CB06/01/0033 CB06/01/0074
Delivery of substances in senescent cells	Diseases where β -Gal is over-expressed	▶						CB06/01/2012